The new Alzheimer's drug Lecanemab is raising great hopes for people with dementia and their caregivers. Very recently, a panel of experts from the European Medicines Agency (EMA) recommended the new active ingredient for treatment – subject to strict conditions. But which patient groups meet the requirements for treatment with Lecanemab? This...
In recent weeks, we have informed you in several parts of our special newsletter SCHLAGLICHT – Medications for Dementia about new dementia drugs and challenges in everyday care. You can reread all published issues at any time in our digiDEM Bavaria newsletter archive: https://digidem-bayern.de/newsletter-archiv/. In the seventh and final issue of our special newsletter SCHLAGLICHT – Medications for Dementia, Michael...
Demenz ist ein komplexes Krankheitsbild mit vielfältigen Ursachen, von denen die Alzheimer-Erkrankung nur eine Erscheinungsform darstellt. Die frontotemporale Demenz ist die zweithäufigste Demenzform vor dem 65. Lebensjahr. Typische erste Symptome sind Verhaltensauffälligkeiten und/oder Sprachstörungen, die meist schon im mittleren Lebensalter auftreten. Dies stellt das familiäre Umfeld von Menschen mit frontotemporaler …
Which factors are associated with falls in people with dementia? Researchers from China investigated this. Their findings provide clear indications of which characteristics to focus on in fall prevention for people with cognitive impairments. While there are numerous studies that examine the risk factors for falls in older individuals...
People with Alzheimer's dementia fall more often than their cognitively healthy peers. Researchers from the USA have now substantiated this finding with a large review. In it, they summarized data on the frequency and number of falls, the reoccurrence rate of falls, and the number of falls that caused injuries. Older people who injured themselves...
In the sixth edition of our special newsletter SCHLAGLICHT – New Medications Against Dementia, Lisa Laininger, research associate at digiDEM Bayern, discusses the publication by Dr. Jeffrey L. Cummings of the University of Nevada Las Vegas and his colleagues, titled Lecanemab: Appropriate Use Recommendations, in the professional journal The Journal of Prevention of Alzheimer’s…
To what extent are mobile health (mHealth) interventions on smartphones, supported by a coach, suitable for reducing dementia risk? Researchers investigated this with a focus on individuals aged 55 to 75 who had a high risk of dementia. The study included, on the one hand, population groups from Great Britain with a low socioeconomic status, and on the other hand, the general population in the greater area of...
In the fifth edition of our special newsletter, SCHLAGLICHT – New Drugs for Dementia, Anne Keefer, a research associate at digiDEM Bayern, discusses the publication by an international group of researchers led by Prof. Alberto J. Espay of the University of Cincinnati. In the article titled "Recalibrating the Risk-Benefit Profiles of Lecanemab..."
Echte Hilfe für Betroffene oder medialer Hype – was können wir von den neuen Medikamenten zur Behandlung der Alzheimer-Erkrankung wirklich erwarten? Weltweit führen Fachexperten kontroverse Diskussionen über die sogenannten monoklonalen Antikörper, die für die Behandlung von leichten kognitiven Beeinträchtigungen und Alzheimer-Demenz vorgesehen sind. Mit den Fakten aus der Forschung werden …
Gender Studies in medicine is a highly relevant societal topic. This is because gender plays an important role in both the development and treatment of diseases. Gender-specific differences are also evident in dementia patients. For example, women develop dementia more often than men and show a different...
